Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Expires | Type | Strike | OI | Change | Percent |
---|---|---|---|---|---|
01/16/2026 | PUT | $250.00 | 1,355 | +196 | +16.91% |
07/25/2025 | CALL | $300.00 | 1,504 | +185 | +14.03% |
09/19/2025 | CALL | $270.00 | 305 | +182 | +147.97% |
09/19/2025 | CALL | $360.00 | 351 | +94 | +36.58% |
09/19/2025 | PUT | $270.00 | 611 | +89 | +17.05% |
07/18/2025 | PUT | $292.50 | 537 | +89 | +19.87% |
09/19/2025 | CALL | $300.00 | 1,327 | -11 | -0.82% |
07/18/2025 | CALL | $305.00 | 2,837 | -25 | -0.87% |
07/18/2025 | CALL | $300.00 | 4,258 | -27 | -0.63% |
07/18/2025 | CALL | $290.00 | 1,884 | -42 | -2.18% |
08/15/2025 | CALL | $325.00 | 661 | -42 | -5.97% |
08/15/2025 | CALL | $305.00 | 932 | -115 | -10.98% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Name | Pct Held | Shares | Total |
---|---|---|---|
Vanguard Total Stock Market Index Fund | 3.04% | 16.22M | 3.66B |
Vanguard 500 Index Fund | 2.31% | 12.33M | 2.78B |
Vanguard/Primecap Fund | 1.71% | 9.12M | 2.06B |
Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 1.31% | 7.02M | 1.58B |
Schwab Strategic Tr-Schwab U.S. Dividend Equity ETF | 1.25% | 6.7M | 1.51B |
Fidelity 500 Index Fund | 1.09% | 5.85M | 1.32B |
SPDR S&P 500 ETF Trust | 1.08% | 5.78M | 1.3B |
SPDR Dow Jones Industrial Average ETF | 1.05% | 5.6M | 1.26B |
iShares Core S&P 500 ETF | 0.89% | 4.76M | 1.07B |
Capital Income Builder, Inc. | 0.89% | 4.74M | 1.07B |
3 Reasons the Schwab U.S. Dividend Equity ETF Is an Attractive Investment for Retirees
07/16 04:25 am
The Motley Fool
Read moreDraig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors
07/15 04:00 am
GlobeNewswire Inc.
Read more1 Top Dividend Growth Stock to Buy Right Now
07/10 04:21 am
The Motley Fool
Read moreWhy I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
07/04 04:30 am
The Motley Fool
Read moreWill Defensive Sectors Keep Driving Dow’s Outperformance This Summer?
07/03 08:30 am
Investing.com
Read moreThis GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
07/01 09:14 pm
The Motley Fool
Read moreWant Decades of Passive Income? Buy This ETF and Hold It Forever.
06/26 10:15 am
The Motley Fool
Read moreAnalyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
06/24 02:54 pm
Benzinga
Read moreGalapagos benoemt Aaron Cox als Chief Financial Officer
06/23 01:30 am
GlobeNewswire Inc.
Read moreArtificial Intelligence (AI) Collaboration, R&D, and Licensing Agreements Trends Report and Directory 2025 | Access to Actual Deals Signed by the World's Leading Biopharma Companies
06/19 10:58 am
GlobeNewswire Inc.
Read moreMembers of Congress Are Pouring Millions Into These 7 Surprising Stocks
06/17 09:33 am
The Motley Fool
Read moreSaudia Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025
06/16 04:00 pm
GlobeNewswire Inc.
Read moreEli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
06/15 07:30 am
The Motley Fool
Read moreRheumatoid Arthritis Global Market Research Report 2025-2035: TNF Inhibitors, IL-6 Inhibitors, and JAK Inhibitors at the Forefront of Developing Biologic Therapies
06/10 04:53 am
GlobeNewswire Inc.
Read moreDilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight
06/05 01:00 pm
GlobeNewswire Inc.
Read moreBispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight
05/29 01:16 pm
GlobeNewswire Inc.
Read moreThe Smartest High-Yielding Dividend Stocks in the Nasdaq Composite Index to Buy With $1,500 Right Now
05/24 07:15 am
The Motley Fool
Read moreU.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
05/24 04:11 am
The Motley Fool
Read moreBetter Weight Loss Stock: Amgen or Viking Therapeutics?
05/22 11:05 am
The Motley Fool
Read moreAplastic Anemia Global Clinical Trials Review, 2025 | Explore Trends and Enrollment Data in Aplastic Anemia Clinical Trials
05/20 06:59 am
GlobeNewswire Inc.
Read moreAmgen CEO Robert A. Bradway to Receive Honorary Degree from KGI
05/08 11:00 am
GlobeNewswire Inc.
Read moreAmgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
05/02 03:57 pm
Benzinga
Read moreLiver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research®
05/02 10:00 am
GlobeNewswire Inc.
Read moreBeat the Nasdaq With This Cash-Gushing Dividend Stock
05/01 08:30 am
The Motley Fool
Read more4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
04/26 06:05 pm
The Motley Fool
Read moreWhy Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
04/22 05:37 pm
The Motley Fool
Read more3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
04/22 09:53 am
The Motley Fool
Read more[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
04/14 10:00 am
GlobeNewswire Inc.
Read moreBiopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline
04/10 05:59 am
GlobeNewswire Inc.
Read moreMinimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
04/08 04:48 am
GlobeNewswire Inc.
Read more3 Dividend Stocks to Buy and Hold for the Next Decade
04/06 06:44 am
The Motley Fool
Read more2 Dividend Stocks to Buy Hand Over Fist in April
04/05 08:30 am
The Motley Fool
Read moreNasdaq 100 Enters Bear Market, Dow In Correction Territory, Traders Await Fed Chair Powell's Remarks
04/04 10:56 am
Benzinga
Read moreFDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder
04/04 10:30 am
Benzinga
Read moreWhy Pharma and Biotech Stocks Got Thrashed on Tuesday
03/25 06:47 pm
The Motley Fool
Read morePharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
03/21 12:31 pm
Benzinga
Read morePrediction: These 2 Stocks Will Outperform the Market Through 2030
03/18 09:53 am
The Motley Fool
Read more5 Reasons the Schwab U.S. Dividend Equity ETF Is a Long-Term Buy for 2030 and Beyond
03/17 07:45 am
The Motley Fool
Read moreBioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - Report by Transparency Market Research, Inc.
03/13 06:00 pm
GlobeNewswire Inc.
Read moreBispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide
03/12 08:48 am
GlobeNewswire Inc.
Read moreIs Eli Lilly Stock a Buy?
03/11 04:10 am
The Motley Fool
Read moreAmgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
03/10 12:50 pm
Benzinga
Read more1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
03/09 06:20 am
The Motley Fool
Read more3 Magnificent Growth Stocks to Buy in March
03/08 11:41 am
The Motley Fool
Read moreInternational Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
03/01 09:45 am
GlobeNewswire Inc.
Read moreThis Could Be the Best GLP-1 Stock to Buy in 2025
02/28 09:45 am
The Motley Fool
Read moreOncology Breakthroughs: How Cancer Research Is Advancing in 2025
02/27 11:04 am
Benzinga
Read moreThese 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
02/25 05:53 am
The Motley Fool
Read moreTALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight
02/24 02:00 pm
GlobeNewswire Inc.
Read moreQuestex’s Fierce Pharma Unveils the Conference Program for the Inaugural Fierce Pharma Engage, Over 100 Speakers Confirmed to Deliver Unparalleled Education
02/24 11:00 am
GlobeNewswire Inc.
Read more